Ever closer to a prophylactic vaccine for HCV

Bibliography

• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52
   PubMed Web of Science ®Google Scholar
• WHO. WHO fact sheet: HCV vaccines number 164. 2012. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ [Last] [accessed 07 February 2013]
   Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
   PubMed Web of Science ®Google Scholar
• Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010;138:315-24
   PubMed Web of Science ®Google Scholar
• Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010;139:965-74
   PubMed Web of Science ®Google Scholar
• Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83
   PubMed Web of Science ®Google Scholar
• Thomas D, Zoulim F. New challenges in viral hepatitis. Gut 2012;61:i1-5
   PubMed Web of Science ®Google Scholar
• Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012;55:695-708
   PubMed Web of Science ®Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-9
   PubMed Web of Science ®Google Scholar
• Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012;61:i36-46
   PubMed Web of Science ®Google Scholar
• Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206
   PubMed Web of Science ®Google Scholar
• Van Den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102:1454-62
   PubMed Web of Science ®Google Scholar
• Hahn JA, Wylie D, Dill J, et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009;1:47-57
   PubMed Web of Science ®Google Scholar
• Simmonds P. Genetic diversity and evolution of hepatitis C virus–15 years on. J Gen Virol 2004;85:3173-88
   PubMed Web of Science ®Google Scholar
• Murphy DG, Willems B, Deschenes M, et al. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. Hepatology 2007;46:623a
   Google Scholar
• Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-44
   PubMed Web of Science ®Google Scholar
• Pybus OG, Barnes E, Taggart R, et al. Genetic history of hepatitis C virus in East Asia. J Virol 2009;83:1071-82
   PubMed Web of Science ®Google Scholar
• Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128:133-47
   PubMed Web of Science ®Google Scholar
• Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49
   PubMed Web of Science ®Google Scholar
• Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012;61:1226-34
   PubMed Web of Science ®Google Scholar
• Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-512
   PubMed Web of Science ®Google Scholar
• Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1-47
   PubMed Web of Science ®Google Scholar
• Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45
   PubMed Web of Science ®Google Scholar
• Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013;35:53-72
   PubMed Web of Science ®Google Scholar
• Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011;60:268-78
   PubMed Web of Science ®Google Scholar
• Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004;305:872-4
   PubMed Web of Science ®Google Scholar
• Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012;56:444-54
   PubMed Web of Science ®Google Scholar
• Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011;60:1284-93
   PubMed Web of Science ®Google Scholar
• Schreiber J, Moreno C, Garcia BG, et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 2012;36:353-62
   PubMed Web of Science ®Google Scholar
• Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706-13
   PubMed Web of Science ®Google Scholar
• Kwak K, Yemelyanova A, Roden RB. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol 2011;23:244-51
   Google Scholar
• Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 2006;78:169-77
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-36
   PubMed Web of Science ®Google Scholar
• Logvinoff C, Major ME, Oldach D, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004;101:10149-54
   PubMed Web of Science ®Google Scholar
• Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007;104:6025
   PubMed Web of Science ®Google Scholar
• Hahn von T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007;132:667-78
   PubMed Web of Science ®Google Scholar
• Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008;14:25-7
   PubMed Web of Science ®Google Scholar
• Perotti M, Mancini N, Diotti RA, et al. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008;82:1047-52
   PubMed Web of Science ®Google Scholar
• Meunier J-C, Russell RS, Goossens V, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008;82:966-73
   PubMed Web of Science ®Google Scholar
• Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011;85:596-605
   PubMed Web of Science ®Google Scholar
• Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004;189:1846-55
   PubMed Web of Science ®Google Scholar
• Abdelwahab SF, Zakaria Z, Sobhy M, et al. Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among egyptian health care workers at high risk of infection. Clin Vaccine Immunol 2012;19:780-6
   PubMed Web of Science ®Google Scholar
• Semmo N. Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy. Blood 2006;107:4570-1
   PubMed Web of Science ®Google Scholar
• Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009;29:843-66
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Fisicaro P, et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006;44:126-39
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002;169:3447-58
   PubMed Web of Science ®Google Scholar
• Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-7
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Jung MC, Gruener NH. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-41
   PubMed Web of Science ®Google Scholar
• Cox AL, Mosbruger T, Lauer GM, et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005;42:104-12
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-55
   PubMed Web of Science ®Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-62
   PubMed Web of Science ®Google Scholar
• Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994;68:8056-63
   PubMed Web of Science ®Google Scholar
• Kaplan DE, Sugimoto K, Newton K, et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 2007;132:654-66
   PubMed Web of Science ®Google Scholar
• Fitzmaurice K, Petrovic D, Ramamurthy N, et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 2011;60:1563-71
   PubMed Web of Science ®Google Scholar
• Kim AY, Kuntzen T, Timm J, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011;140:686-696.e1
   PubMed Web of Science ®Google Scholar
• Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun 2007;8:181-92
   PubMed Web of Science ®Google Scholar
• Dazert E, Neumann-Haefelin C, Bressanelli S, et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009;119:376-86
   PubMed Web of Science ®Google Scholar
• Rehermann B, Chang KM, McHutchison JG, et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996;98:1432-40
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Depla E, Hulstaert F, et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004;22:3080-6
   PubMed Web of Science ®Google Scholar
• Verstrepen BE, Depla E, Rollier CS, et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011;204:837-44
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-8
   PubMed Web of Science ®Google Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436:961-6
   PubMed Web of Science ®Google Scholar
• Frey SE, Houghton M, Coates S, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010;28:6367-73
   PubMed Web of Science ®Google Scholar
• Drane D, Maraskovsky E, Gibson R, et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a Phase I study in healthy volunteers. Hum Vaccin 2009;5:151-7
   PubMed Web of Science ®Google Scholar
• Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456-62
   PubMed Web of Science ®Google Scholar
• Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006;24:4343-53
   PubMed Web of Science ®Google Scholar
• Firbas C, Boehm T, Buerger V, et al. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 2010;28:2397-407
   PubMed Web of Science ®Google Scholar
• Klade CS, Schuller E, Boehm T, et al. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 2012;30:2943-50
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008;134:1385-95
   PubMed Web of Science ®Google Scholar
• Sallberg M, Frelin L, Weiland O. DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Expert Opin Biol Ther 2009;9:805-15
   PubMed Web of Science ®Google Scholar
• Ahlen G, Nystrom J, Pult I, et al. In vivo clearance of hepatitis C virus nonstructural 3/4A–expressing hepatocytes by DNA vaccine–primed cytotoxic T lymphocytes. J Infect Dis 2005;192:2112-16
   PubMed Web of Science ®Google Scholar
• Alvarez-Lajonchere L, Shoukry NH, Gra B, et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16:156-67
   PubMed Web of Science ®Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ, et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45:602-13
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006;12:190-7
   PubMed Web of Science ®Google Scholar
• Fattori E, Zampaglione I, Arcuri M, et al. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming–boosting with novel adenoviral vectors based on different serotypes. Gene Ther 2006;13:1088-96
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012;4:115ra1
   PubMed Web of Science ®Google Scholar
• Park SH, Shin EC, Capone S, et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology 2012;143:1048-460
   PubMed Web of Science ®Google Scholar
• Youn JW, Hu YW, Tricoche N, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 2008;82:10896-905
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93
   PubMed Web of Science ®Google Scholar
• Brave A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol Pharm 2007;4:18-32
   PubMed Web of Science ®Google Scholar
• Lin Y, Kwon T, Polo J, et al. Induction of broad CD4+ and CD8+ T-cell responses and cross- neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 2008;82:7492-503
   PubMed Web of Science ®Google Scholar
• Pancholi P, Perkus M, Tricoche N, et al. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 2003;77:382-90
   PubMed Web of Science ®Google Scholar
• Wuest T, Both GW, Prince AM, et al. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 2004;22:2717-21
   PubMed Web of Science ®Google Scholar
• Brinster C, Chen M, Boucreux D, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 2002;83:369-81
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong S-H, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007;104:8427-32
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Chen L, Fu T-M, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-13
   PubMed Web of Science ®Google Scholar
• Tatsis N, ERTL H. Adenoviruses as vaccine vectors. Mol Ther 2004;10:616-29
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Sci Transl Med 2012;4:115ra2-2
   PubMed Web of Science ®Google Scholar
• Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93. doi:10.1038/nature10766
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Rollier CS, Milicic A, et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2009;20:1633-47
   Google Scholar
• Reyes-Sandoval A, Wyllie DH, Bauza K, et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011;187:1347-57
   PubMed Web of Science ®Google Scholar
• Capone S, Reyes-Sandoval A, Naddeo M, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA primea€“boost immunisation in non-human primates. Vaccine 2010;29:256-65
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Identifier: NCT01296451. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01296451 [Last accessed 21 March 2013]
   Google Scholar
• ClinicalTrials.gov Identifier: NCT01436357. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01436357 [Last accessed 21 March 2013]
   Google Scholar
• Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011;239:99-108
   PubMed Web of Science ®Google Scholar
• Spada E. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004;53:1673-81
   PubMed Web of Science ®Google Scholar
• Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004;127:924-36
   PubMed Web of Science ®Google Scholar
• Makedonas G, Betts MR. Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev 2010;239:109-24
   Web of Science ®Google Scholar
• Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010;33:451-63
   PubMed Web of Science ®Google Scholar
• Newell EW, Sigal N, Bendall SC, et al. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 2012;36:142-52
   PubMed Web of Science ®Google Scholar
• Erickson AL, Kimura Y, Igarashi S, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-95
   PubMed Web of Science ®Google Scholar
• Puig M, Mihalik K, Tilton JC, et al. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006;44:736-45
   PubMedGoogle Scholar
• Klenerman P. Viral escape and the failure of cellular immune responses. Science 2000;289:2003a–2003
   PubMedGoogle Scholar
• Stamataki Z, Coates S, Abrignani S, et al. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011;204:811-13
   PubMed Web of Science ®Google Scholar
• Spangenberg HC, Viazov S, Kersting N, et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology 2005;42:828-37
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9
   PubMed Web of Science ®Google Scholar
• Kannanganat S, Ibegbu C, Chennareddi L, et al. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007;81:8468-76
   PubMed Web of Science ®Google Scholar
• Bogdan C, Moll H, Solbach W, Rollinghoff M. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 1990;20:1131-5
   PubMed Web of Science ®Google Scholar
• Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007;204:1405-16
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-58
   PubMed Web of Science ®Google Scholar
• La Gruta NL, Turner SJ, Doherty PC. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J Immunol 2004;172:5553-60
   PubMed Web of Science ®Google Scholar
• Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104-6
   PubMed Web of Science ®Google Scholar
• Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002;99:15661-8
   PubMed Web of Science ®Google Scholar
• Lechner F, Sullivan J, Spiegel H, et al. Why do cytotoxic T lymphocytes fail to eliminate hepatitis C virus? Lessons from studies using major histocompatibility complex class I peptide tetramers. Philos Trans R Soc Lond B Biol Sci 2000;355:1085-92
   PubMed Web of Science ®Google Scholar
• Bots M, Medema JP. Granzymes at a glance. J Cell Sci 2006;119:5011-14
   PubMed Web of Science ®Google Scholar
• Peters PJ, Borst J, Oorschot V, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 1991;173:1099-109
   PubMed Web of Science ®Google Scholar
• Makedonas G, Hutnick N, Haney D, et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8+ T cells. PLoS Pathog 2010;6:e1000798
   PubMedGoogle Scholar
• Jo J, Bengsch B, Seigel B, et al. Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. J Hepatol 2012;57:9-16
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12
   PubMed Web of Science ®Google Scholar
• Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry 2008;73A:975-83
   Google Scholar
• Appay V, Rowland-Jones SL. Lessons from the study of T-cell differentiation in persistent human virus infection. Semin Immunol 2004;16:205-12
   PubMed Web of Science ®Google Scholar
• Merkenschlager M, Terry L, Edwards R, Beverley PCL. Limiting dilution analysis of proliferative responses in human lymphocyte populations defined by the monoclonal antibody UCHL1: implications for differential CD45 expression in T cell memory formation. Eur J Immunol 1988;18:1653-62
   PubMed Web of Science ®Google Scholar
• Kaech SM, Tan JT, Wherry EJ, et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-8
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-7
   PubMed Web of Science ®Google Scholar
• Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 2007;27:393-405
   PubMed Web of Science ®Google Scholar
• Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009;15:293-9
   PubMed Web of Science ®Google Scholar
• Flatz L, Roychoudhuri R, Honda M, et al. Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proc Natl Acad Sci USA 2011;108:5724-9
   PubMed Web of Science ®Google Scholar
• Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007;110:1916-23
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Zhong X-S, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 2009;15:808-13
   PubMed Web of Science ®Google Scholar
• Masopust D, Ha S-J, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol 2006;177:831-9
   PubMed Web of Science ®Google Scholar
• Ahmed R, Akondy RS. Insights into human CD8+ T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 2011;89:340-5
   PubMed Web of Science ®Google Scholar
• Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler's guide to cytometry. Trends Immunol 2012;33:323-32. doi:10.1016/j.it.2012.02.010
   PubMed Web of Science ®Google Scholar
• Krahn MD, John-Baptiste A, Yi Q, et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005;23:1549-58
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8
   PubMed Web of Science ®Google Scholar